A review and meta analysis of health state utility values in breast cancer by Peasgood, T. et al.
-1  
 
 
 
 
 
 
 
 
 
HEDS Discussion Paper 10/12 
 
 
 
 
 
 
 
Disclaimer: 
This is a Discussion Paper produced and published by the Health Economics 
and Decision Science (HEDS) Section at the School of Health and Related 
Research (ScHARR), University of Sheffield.     HEDS Discussion Papers are 
intended  to  provide  information  and  encourage  discussion  on  a  topic  in 
advance of formal publication.  They represent only the views of the authors, 
and do not necessarily reflect the views or approval of the sponsors. 
 
White Rose Repository URL for this paper: 
    http://eprints.whiterose.ac.uk/11227/ 
 
Once a version of Discussion Paper content is published in a peer-reviewed 
journal, this typically supersedes the Discussion Paper and readers are invited 
to cite the published version in preference to the original version. 
 
Published paper 
Peasgood, T., Ward SE, Brazier J., Health-state Utility values in breast cancer. Expert 
Review, Pharmacoeconomics Outcomes Research. 10(5): 553-566. October 2010. 
 
 
 
White Rose Research Online 
eprints@whiterose.ac.uk 
-2  
 
ScHARR 
SCHOOL OF HEALTH AND 
 
RELATED  RESEARCH 
1  
Health-state Utility values in breast cancer 
 
 
 
 
 
 
 
 
Peasgood, T, Ward SE, Brazier J. 
 
 
 
 
Health Economics and Decision Science 
School of Health and Related Research 
University of Sheffield 
30 Regent Street 
 
Sheffield 
 
 
 
 
Email:  j.e.brazier@sheffield.ac.uk 
 
 
 
 
 
 
Keywords: utility, combining, comorbid, quality of life 
 
 
 
 
Word count: 7,176 
2  
ABSTRACT 
 
Background: Analysts frequently estimate the health state utility values (HSUVs) for 
combined health conditions (CHCs) using data from cohorts with single health conditions. 
The methods used to estimated the HSUVs can produce very different results and there is 
currently no consensus on the most appropriate technique that should be used. 
 
 
 
Objective: To conduct a detailed critical review of existing empirical literature to gain an 
understanding of the reasons for differences in results and identify where uncertainty remains 
that may be addressed by further research. 
 
 
 
Results: Of the eleven studies identified, ten assessed the additive method, ten the 
multiplicative method, seven the minimum method, and three the combination model. Two 
studies evaluated just one of the techniques while the others compared results generated using 
two or more. The range of the HSUVs can influence general findings and methods are 
sometimes compared using descriptive statistics that may not be appropriate for assessing 
predictive ability.  None of the proposed methods gave consistently accurate results across the 
full range of possible HSUVs and the values assigned to normal health influence the accuracy 
of the methods. 
 
 
 
Conclusions: While there is no unequivocal evidence for supporting one particular method, 
the combination linear model appeared to give more accurate results in the studies reviewed. 
However, before a method can be recommended, research is required in datasets covering the 
full range of the preference-based indices and health conditions typically defined in decision 
analytic models. The methods used to assess performance and the statistics used when 
reporting results require improvement in general. 
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BACKGROUND 
 
To fulfil demands from policy decision makers in health care, there has been a growth in the 
number of economic evaluations of interventions in health care reporting results in terms of 
cost per quality adjusted life years (QALY). The QALY combines both survival and health 
related quality of life (HRQoL) into a single metric that facilitates comparison of results 
across disparate interventions and disease areas thus allowing optimal allocation of resources. 
Many decision making bodies require that HRQoL data used in economic evaluations are 
derived from preference-based utility measures with weights obtained from members of the 
general public.[1] These preference-based measures generate an index of health state utility 
values (HSUVs) whereby perfect health and death are anchored at one and zero respectively 
and negative values represent health states considered to be worse than death. The most 
frequently used generic instruments are the EQ-5D, the HUI and the SF-6D.[2-4] 
 
 
 
Economic models in health care describe the clinical pathway of health conditions. They can 
become quite complex involving health states representing the primary health condition and 
additional health states representing comorbidities where an additional condition exists 
concurrently with the primary health condition.  For example, a comorbid health condition 
(CHC) would be a woman with osteoporosis who then develops breast cancer, while an 
adverse event might be someone with influenza developing nausea as a side effect of 
treatment given for influenza.  HSUVs used to inform health states are often collected in the 
clinical studies assessing the effectiveness of treatments under evaluation. When these data 
are not available, HSUVs may be elicited directly from patients or sourced from the literature. 
While the former has the advantage that the health states valued can be precisely defined to 
match those in an economic model, they are resource intensive and the end product is not the 
preferred data for policy decision making.[1]  The latter is problematic as while there is a 
substantial evidence base providing HSUVs for individuals with single health conditions, the 
volume of data describing HSUVs for CHCs is limited.  Consequently analysts frequently 
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estimate the HSUVs for CHCs using data from cohorts with single health conditions and 
assumptions about how they should be combined. 
 
 
 
A number of different approaches have been adopted in practice and recent literature has 
sought to provide empirical evidence for these alternatives.  However, this is limited and there 
is currently no consensus on which is the most suitable approach. As the technique used to 
estimate HSUVs for CHCs could potentially influence a policy decision based on a cost per 
QALY threshold,[5] inconsistencies in the approaches used could undermine optimal 
allocation of scarce health care resources. 
 
 
 
The objective of the current study is to conduct a detailed critical review of existing empirical 
literature. This will permit an understanding of the reasons for differences in the results, 
identify hypotheses that are consistent with the empirical evidence and identify where 
uncertainty remains that may be addressed by further research.  As HSUVs for CHCs in 
economic models are generally estimated using summary statistics from generic instruments 
reported in the literature, the greatest interest is on studies that use mean HSUVs from cohorts 
with single health conditions to estimate mean HSUVs for CHCs 
 
 
 
The following section introduces the methods frequently used to estimate HSUVs for CHCs 
with a summary of obvious limitations. This is followed by a brief description of the 
literature search, a synopsis of the studies identified and their corresponding datasets . The 
next section provides details of the methods used to estimate HSUVs for CHCs in each of the 
studies. This is followed by a section describing the results and the statistics used when 
comparing results and drawing conclusions. We culminate with a summary of the evidence 
base and suggestions for future research. Throughout the article, emphasis is placed on 
determining differences in the studies and methodologies which may explain the contradictory 
findings reported. 
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Baseline HRQoL 
 
Before describing the methods used to estimate HSUVs for CHCs it is useful to consider the 
“baseline” utility. The “baseline” utility is defined as the HSUV a person would have if they 
did not have a particular health condition and the impact on HRQoL attributable to a health 
condition is defined as the difference between the HSUV associated with the particular health 
condition and the baseline. The baseline utility used can make a large difference to the 
estimated decrement on HRQoL associated with particular conditions as shown in the 
following example.  Using EQ-5D data (range -0.59 to 1) collected from a random sample 
(n=41471) of the UK population, the mean HSUV for a cohort with “a history of heart 
attack/angina” is 0.632 (Figure 1) and the mean age for the cohort is 70 years.[6] The impact 
on HRQoL attributable to avoiding a heart attack/angina is 0.368 (0.368 = 1 – 0.632) when 
assuming a baseline of perfect health and 0.181 (0.181 = 0.813 – 0.632) when assuming the 
baseline is the average health for individuals of the same age with no history of heart 
attack/angina. Similarly, looking at the condition “arthritis/rheumatism”, the impact on 
HRQoL attributable to arthritis/rheumatism is 0.403 (0.403 = 1 – 0.597) when assuming a 
baseline of perfect health and 0.272 (0.272 = 0.869 – 0.597) when assuming the baseline is 
the average health for individuals of the same age who do not have a history of 
arthritis/rheumatism.  The differences in the decrements (0.187 = 0.368 - 0.181 for heart 
attack/angina, 0.131 = 0.403 - 0.272) for arthritis/rheumatism) may be attributable to other 
factors such as comorbidities and age.[7]  If a baseline of perfect health is used to estimate the 
decrements associated with the single health conditions and these data are then used to 
estimate the decrements associated with a CHC, the impact on HRQoL associated with other 
factors will be counted twice. 
 
 
 
 
 
INSERT Figure 1: Impact on HRQoL attributable to health condition(s) 
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The alleviation of a particular health condition will not restore the HRQoL of the average 
person to full health as they will still have other health problems and it has been suggested 
that, on average, a treatment will increase HRQoL to the same level of persons without the 
condition.[8]  Several approaches have been taken to adjust the baseline when estimating 
HSUVs for CHCs. These include: “purifying” data by dividing all HSUVs by the average 
HSUV obtained from individuals who report none of the health conditions identified in a 
survey;[9,10] using condition specific data obtained from individuals who do not report the 
particular health condition(s) of interest,[11] using age adjusted data obtained from 
individuals who report none of the health conditions identified in a survey.[12,13] 
 
 
 
Methods Used To Estimate HSUVs For Comorbid Health Conditions 
 
The techniques described below use mean HSUVs from cohorts with single health conditions 
to estimate mean HSUVs for cohorts with CHCs. There are three main methods used to 
estimate the utility value for a combined health state when data only exist for relevant single 
health states. These can be termed the “additive”, “multiplicative” and “minimum” 
approaches.  Alternatives recently proposed include: the adjusted decrement estimator (ADE) 
which is a variation of the minimum method, and a simple linear model, based on multi- 
attribute utility theory and prospect theory, which incorporates terms representing the 
additive, multiplicative and minimum methods.[10,14] 
 
 
 
Given two health conditions, condition A and condition B, there are four possible 
combinations of these conditions: individuals have condition A but not condition B, 
individuals have condition B but not condition A, individuals have both condition A and 
condition B; individuals do not have either condition A or condition B. The HSUVs 
associated with these four alternatives are defined as: UA, UB, UA,B, and UnA,nB. 
 
 
Additive method. The additive method assumes a constant absolute decrement relative to the 
baseline and the estimated HSUV for the additive CHC is calculated using: 
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where the superscript “add” denotes the additive method. 
 
If a baseline of perfect health is used, the additive method can be calculated using: 
 
A, B  = U A  + U B  − 1 (Eqn 2) 
 
 
 
 
Multiplicative method. The multiplicative method assumes a constant proportional decrement 
 
relative to the baseline and the estimated HSUV is calculated using: 
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where the superscript “Mult” denotes the multiplicative method. 
 
If a baseline of perfect health is used, the multiplicative method can be calculated using: 
 
A, B   = U A ⋅ U 
 
B 
(Eqn 4) 
 
 
 
 
Minimum method. The minimum method assumes the decrement on HRQoL associated with 
a comorbidity is equal to the maximum decrement attributable to the individual single health 
conditions, and the estimated HSUV is calculated using: 
U A, B  = min(U nA,nB ,U A ,U B ) (Eqn 5) 
 
where the superscript “min” denotes the minimum method. 
 
If a baseline of perfect health is used, the minimum method can be calculated using: 
 
U A, B  = min(U A ,U B ) (Eqn 6) 
 
 
 
 
Adjusted decrement estimator. The adjusted decrement estimator (ADE) has recently been 
proposed as an alternative method to estimate HSUVs for CHCs. This estimator is a variation 
of the minimum method and assumes the estimated HSUV for the CHC has an upper bound 
equal to the minimum of the HSUVs from the two single health conditions. The proposed 
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method is described by: 
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where the superscript “ADE” denotes the adjusted decrement estimator. 
 
 
 
 
Combination model. Basu et al. recently proposed a simple linear model which incorporates 
terms representing the additive, multiplicative and minimum methods.[14] The model is 
formulated from a) an adaptation of work originally presented by Keeny and Raiffa (1976, 
1993) which was based on decision theory and multi-attribute utility functions,[15-16] and b) 
a prospect theory that proposes the value function is convex for losses with a marginal rate of 
decrement in value with increasing losses, as presented by Tversky and Kahneman 
(1992).[17] The model is defined by: 
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where the superscript “comb” denotes the combination model, ε the residual and the beta 
coefficients are obtained using ordinary least square regressions.  Equation 8 uses a baseline 
of perfect health. Using an adjusted baseline, the combination model can be defined by: 
U A,B     = β 0  + β1 ⋅ min((U nA  − U A ), (U nb  − U B )) + β ⋅ max((U nA  − U A ), (U nb  − U B )) 
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The combination model reduces to the three traditional methods under the following 
conditions:[14] 
When β0 = 0, β1 = 1, β2 = 1 and β3 = 0, then Eqn 8 collapses to Eqn 2 (additive method) 
 
When β0 = 0, β1 = 1, β2 = 1 and β3 = -1, then Eqn 8 collapses to Eqn 4 (multiplicative method) 
When β0 = 0, β1 = 1, β2 = 0 and β3 = 0, then Eqn 8 collapses to Eqn 6 (minimum method) 
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There are a number of limitations with the methods described above including access to the 
required baseline data, combining negative HSUVs and estimating HSUVs for CHCs that 
consist of more than two health conditions.  Sourcing appropriate baseline data will be 
difficult as ideally each health condition requires a unique baseline obtained from individuals 
who do not have the specific condition(s). While these data may be derived from large 
datasets, due to the enormous number of possible combinations of health conditions, in 
practice the required data may not be readily available. For some preference based measures 
such as the EQ-5D or the HUI3, it is possible to have negative HSUVs for one or more of the 
single health conditions. This has implications for both the additive and multiplicative 
methods.  For the additive method, the decrements associated with the single health 
conditions can be relatively large if negative HSUVs are involved thus the resulting estimated 
HSUV for the CHC could be outside the lower limit of the preference based index. The 
multiplicative method is not valid if used to combine an even number of negative HSUVs as 
the estimated HSUV for the CHC will be positive (i.e. higher than either of the HSUVs for 
the single health conditions).  While it is simple to incorporate additional conditions into the 
multiplicative and minimum methods, multiple health conditions will be problematic when 
using the additive method as again the sum of the corresponding decrements could produce 
HSUVs below the lower limit of the preference based index. 
 
 
 
 
 
LITERATURE SEARCH and SYNOPSIS OF STUDIES INCLUDED 
 
A systematic literature search of the following databases: Cinahl, the Cochrane library, 
Embase, Medline, PsycInfo and Web of Science, was carried out using keywords combining 
variations of terms for HRQoL (e.g. health state utility, quality of life, Euroqol, EQ5D, health 
utilities mark, HUI, short form six D, SF-6D etc), methodological terms (e.g. standard 
gamble, SG, time trade off, TTO, additive, multiplicative, minimum, regression, model) and 
terms for joint health states (e.g. joint health state, comorbid, combined health states, 
concurrent, multiple).  Based on a few core papers identified, a citation search was carried out 
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using the Web of Knowledge and Google Scholar databases. The citation search was 
undertaken both forwards and backwards. The forward search ensures that all papers that cite 
the core papers are reviewed.  The backwards search ensures that all papers cited by the core 
papers are reviewed. Reference lists of all papers included in the review were checked for 
additional relevant articles. The searches were not restricted by publication type, language, or 
date of publication. 
 
 
 
Synopsis of studies included 
 
The number of relevant papers was reduced to 11 based on a review of the titles and abstracts. 
Papers were not assessed on the basis of study design, setting or quality, only on whether they 
involved estimating or predicting HSUVs for CHCs using data from single health conditions. 
The aim of the review was to examine the literature to gain an understanding of possible 
reasons for differences in results and conclusions drawn with a view to informing future 
research in this area. This was addressed by extracting data reported to describe model fit, 
performance, diagnostics and the main conclusions reported by the authors (Table 1). 
 
 
 
INSERT Table 1: Synopsis of studies included in the review 
 
 
 
 
Three of the studies used data directly elicited from patients, using the same people to value 
HSUVs for both single and combined health conditions.[14,18-19]  HSUVs for the single 
health conditions were then used to estimate HSUVs for the CHCs and accuracy in the 
estimates were compared with the actual HSUVs on an individual level. The eight remaining 
studies used large databases where preference-based data were obtained using responses to 
generic quality of life questionnaires.[9-13,20-22]  Six of these studies used mean HSUVs 
obtained from subgroups with single health conditions to estimate mean HSUVs for 
subgroups with CHCs.[9-13,21] The remaining two studies used regressions to explore the 
relationship between HSUVs and presence of health conditions using individual level 
data.[20,22] 
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Of the three studies that elicited HSUVs directly from patients; two used data obtained from 
patients (n= 147,[18] n=207[14]) with recurrent rectal cancer whereby a trade-off was made 
between remaining in a described health state for the duration of life expectancy versus living 
in perfect health for a shorter period of time.  Single health conditions were defined as 
“impotence”, “incontinence”, “watchful waiting” and “post-prostatectomy without 
complications”, and CHCs were defined as “impotence” plus one of the other three SHCs. 
The third, which is published in abstract form only, used HSUVs elicited using standard 
gamble from patients with recurrent rectal cancer.[19] Single health conditions were defined 
as: “cancer”, “pain”, “complications”, and “surgery”; and CHCs were defined as: “cancer and 
pain”, “cancer and complications”, and “residual cancer after surgery”. 
 
 
 
The eight studies that used preference-based HSUVs obtained from generic HRQoL 
questionnaires evaluated data (range 5,224 [22] to 131,535 respondents [9]) from large 
surveys.  Four used EQ-5D,[10-12,21] three used SF-6D,[13,20,22] and one used HUI3 
data.[9] The definitions for the health conditions in the primary surveys ranged from specific 
conditions such as “diabetes mellitus without complications”[21] and “asthma”[11] to more 
general definitions such as “back problems”,[9] “cancer (neoplasm) including lumps, 
mass”,[12] “musculoskeletal or arthritis/rheumatism/fibrositis”.[13]  One of the studies was 
slightly different in that it concentrated on data from individuals with: just diabetes, diabetes 
plus hypertension, diabetes plus heart disease, or diabetes plus musculoskeletal illnesses.[22] 
 
 
 
Number of CHCs and range of estimated HSUVs 
 
In each case the three studies using the directly elicited data estimated HSUVs for just three 
CHCs (Table 1 and Table 2).[14,18-19].  In contrast, the majority of the studies using 
responses from generic HRQoL questionnaires estimated HSUVs for much larger numbers of 
pairs of CHCs (range: 32[13] to 760[21]).  In addition to predicting HSUVs for CHCs, one 
study also examined the relationship between SF-36 health dimensional scores for single 
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health conditions and CHCs,[22] while another study estimated results for CHCs involving 
more than two conditions.[9] 
 
 
 
For the studies using the elicited data, the actual HSUVs for the CHCs were all 0.5 (medians) 
in one study[19] and covered the ranges 0.66 to 0.72 (means),[18] and 0.63 to 0.70 
(means)[14] in the other two.  Possible ranges for the preference-based indices for the generic 
HRQoL questionnaires used are: SF-6D range: 0.3 to 1; EQ-5D range: -0.59 to 1; HUI3 range 
-0.36 to 1.  None of the studies analysing these data estimated mean HSUVs that covered the 
full ranges of the indices. The smallest range in actual mean HSUVs was for EQ-5D data 
(0.734 to 0.819) from the US Medical Expenditures Panel Survey (MEPS 2000, 2002)[11] 
and the largest range was for HUI3 data (-0.01 to 1.00) from the Canadian Community Health 
Survey (2001, 2003).[9] The authors of the latter study reported that while there was a wide 
variation in the mean HUI3 scores for subgroups with CHCs, the majority (184/278) were 
greater than 0.80. Conversely, two thirds of the actual mean EQ-5D HSUVs for the CHCs 
identified in a study using data from the Health Survey for England were below 0.60 (range 
0.360 to 0.917).  Obviously the range in actual HSUVs is highly relevant when comparing 
accuracy of the different techniques as the method should be generalisable for use across the 
full utility index including negative values where applicable. 
 
 
 
 
 
METHODS USED TO ESTIMATE HSUVs for CHCs 
 
Baseline HRQoL 
 
When estimating HSUVs for the CHCs, the three studies analysing directly elicited data used 
a baseline of perfect health.[14,18-19]  I.e. when the elicited data for the single health 
conditions were used to estimate HSUVs for CHCs, the decrements on HRQoL were 
calculated using a baseline of perfect health. Flanagan et al. “purified” their data by dividing 
all age and sex standardised HSUVs by the mean HSUV (HUI3 = 0.94) from respondents 
reporting none of the health conditions identified in the primary survey.[9]  The objective of 
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the purification was to remove the loss of functional health due to health problems other than 
the chronic conditions reported in the primary survey.[9]  Fu and Kattan used a similar 
approach in secondary analyses; dividing the HSUVs by the mean HSUV (EQ-5D = 0.952) 
from respondents reporting none of the health conditions in their dataset, and presented 
results using a baseline of perfect health as the primary analyses.[21]  Ara and Brazier 
estimated age-adjusted baselines using HSUVs from respondents reporting none of the health 
conditions identified in the primary surveys[12-13] and Janssen used mean values from the 
respondents who did not report either condition in each individual CHC for the baseline.[11] 
 
 
 
Methods used to estimate or predict HSUVs for CHCs 
 
Table 2 provides an indication of the methods compared in each of the studies. The studies 
are subgrouped into those (n=3) using directly elicited HSUVs and those (n=8) using HSUVs 
obtained from generic HRQoL instruments. The latter are further subgrouped into the two 
studies predicting HSUVs from regression models and the six studies estimating mean 
HSUVs for CHCs using mean HSUVs from subgroups with single health conditions. 
 
 
 
Ten studies assessed the additive method, ten the multiplicative method, seven the minimum 
method, and three the combination model. Two studies[9,22] evaluated just one of the 
techniques while the others compared results generated using two,[11,19] three,[18,20-21] or 
more techniques.[10,12-13,14] 
 
 
 
INSERT TABLE 2: Reported results and supporting statistics 
 
 
 
 
REPORTED RESULTS 
 
Studies using utilities elicited directly from patients 
 
Of the three studies using the elicited HSUVs,[14,18-19] Esnaola reported the median 
absolute difference between the actual and estimated HSUVs for the multiplicative method 
was significantly lower than that for the additive method (Wilcoxon signed ranks test, 
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p<0.001).[19]  Dale assessed bias in the estimated HSUVs, assuming an unbiased method 
would give a mean error (ME) insignificantly different from zero and errors uncorrelated with 
estimated HSUVs.[18] They reported the additive, minimum and multiplicative methods all 
produced biased estimates (ME: range 0.038 to 0.127, p<0.05, correlations: range -0.305 to - 
0.533, p<0.05.[18] While the minimum method had the smallest RMSE (0.194) and the 
smallest MAE (0.260), plots showed higher HSUVs were substantially under-predicted and 
lower HSUVs substantially over-predicted demonstrating that mean statistics are not 
particularly informative or useful for comparison purposes. The authors recommended 
HSUVs for CHCs should be elicited directly as the additive, multiplicative and minimum 
methods are biased and inefficient.  If an elicitation exercise is not possible they recommend 
the minimum method.[18] Basu reported the combination model (UA,B = 1 – (0.05 + 
0.72*max (1-UA, 1–UB)+0.33*min(1-UA, 1–UB) -0.18*(1-UA)(1–UB)) produced up to 50% 
 
reduction in the MSE compared to the three traditional methods (additive, multiplicative, 
minimum).[14]  The correlations between the residuals and predicted HSUVs were much 
smaller (range 0.0006 to 0.0682 when subgrouped by CHC) for the combination model 
compared to the correlations between the errors and estimated HSUVs for the other methods 
(< - 0.246 for all CHCs and methods).  Plots of the mean residuals across quartiles of 
estimated HSUVs, showed the four mean residuals from the combination model were close to 
zero while the other three methods over-estimated low HSUVs and under-estimated high 
HSUVs. 
 
 
 
There are difficulties when generalising from these findings and concerns regarding the validity 
and generalisability of the results.  First, there are problems with the definitions of the health 
conditions valued. For example, the health states “cancer” and “pain” used in two of the studies 
are not mutually exclusive as the condition cancer intuitively involves pain, similarly, 
comparing a diagnosis of recurrent cancer, “incontinence” appears trivial.[14,18] 
In the third study, “watchful waiting” relates to a management strategy as opposed to a health 
condition.[19]  Second, the studies used the same participants to value both the single health 
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conditions and the CHCs consequently the value attributed to the CHC could be influenced by 
the value given to the single condition(s). Self-correction prompts in the TTO software were 
not employed in two of the studies[14,18] and 28-40% of valuations were inconsistent in that 
the elicited HSUVs for the CHC were greater than those for the corresponding single health 
conditions.[23] Third, the actual CHC HSUVs in all three studies covered a very narrow 
range of possible values, limiting generalisability.  Finally, it is not clear if the OLS model 
obtained will perform well in external data. 
 
 
 
These limitations withstanding, when estimating HSUVs for CHCs using data elicited directly 
from patients, the authors findings can be ranked as follows. When comparing the additive and 
multiplicative methods alone, the multiplicative method is best.[19]  Comparing the additive, 
multiplicative and minimum methods, the minimum is best followed by the multiplicative and 
then the additive.[18]  Comparing all four methods, the combination model is more accurate 
than the others with the minimum method being better than the 
multiplicative method which is better than the additive method.[14]  However, these findings 
are based on analyses using a very limited range of HSUVs for the CHCs and the coefficients 
in the combination model may not be generalisable to external data. This draws attention to 
the danger in drawing conclusions from analyses comparing a limited number of the 
alternative estimating methods. 
 
 
 
Studies using individual level data obtained from generic HRQoL instruments 
 
Of the two studies using the individual level data obtained from generic HRQoL instruments 
(both SF-6D), Wee et al. favoured the additive method while Hanmer et al. favoured the 
multiplicative method.[20,22]  Wee et al. derived three linear models (n=5,224) with one pair 
of CHCs (diabetes plus either hypertension, heart disease or musculoskeletal illnesses) in each 
model.[22] The dependent variable was the SF-6D and independent variables were: diabetes, 
one of the second chronic medical conditions, the interaction between these, and socio- 
demographic variables. The regressions were used to determine if the combined independent 
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effects of two single health conditions were additive (i.e. the effect is equal to the sum of the 
two independent effects and the interaction term is not significant), subtractive (i.e. the effect is 
smaller than the sum of the two independent effects and the interaction term is significant and 
positive), or synergistic (i.e. the effect is greater than the sum of the two independent effects 
and the interaction term is significant and negative).[22]  While the coefficients for both single 
health conditions were negative and statistically significant (p<0.05) in each of the three 
regressions, the interaction term was reported to be not significant (coefficients and p- values 
not reported), implying the combined effect was additive with no evidence of either a 
synergistic or subtractive effect. 
 
 
 
Hanmer et al. compared the additive, multiplicative and minimum methods in regressions 
(n=5,969 under 65 years; n=89,226 for 65 and over) using a latent define summary health 
scale censored at 0.30 and 1 to match the boundaries of the SF-6D.[20] The 
utilities/disutilities associated with numbers of health conditions were entered as independent 
variables (from no conditions up to a maximum of 12 or more conditions) and models were 
obtained with/without socio-demographic covariates. The minimum method used the same 
model form but entered individuals as having the health condition with the greatest aggregate 
impact on health utility.  In addition to evaluating the models’ performance in terms of 
accuracy in predicted scores for individuals, results were also reported for subgroups 
identified by the number of CHCs.  For respondents aged 65 years and over, the 
multiplicative (minimum) model had the smallest (largest) ME and MSE when subgrouped by 
number of health conditions.  Box plots describing errors (actual mean minus predicted mean) 
for subgroups with two or three CHCs showed a much larger variation in errors from the 
minimum model compared to the other two. While the vast majority of errors for the additive 
and multiplicative models were within the reported minimally important difference for the 
SF-6D (0.03 to 0.04),[24-25] there were several outliers beyond these limits. The authors 
concluded that all the methods were imperfect with the multiplicative linear model 
performing best followed by the additive linear model and the minimum linear model. They 
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cautioned that the analyses should be replicated in other large datasets before making strong 
recommendations on the best methodology and in particular mentioned that censoring at the 
limits of the SF-6D index could be important in skewed data sets. 
 
 
 
It is not possible to determine the most accurate method for predicting HSUVs for CHCs 
using the findings of these two studies. As the CHCs used in Wee’s study were limited to 
diabetes plus one other health condition, this limits generalisability of results to other 
CHCs.[22] The findings from Hanmer’s study are also limited due to the potentially small 
range in actual HSUVs evaluated where the decrement on utility was reported to be relatively 
small (-0.02 to -0.03) for the majority of the single health conditions.[20] 
 
 
 
Studies using mean data obtained from generic HRQoL instruments 
 
Of the six studies that used mean HSUVs from subgroups with single health conditions to 
estimate mean HSUVs for CHCs, one found the multiplicative method gave a good fit 
(synergy coefficient = 0.99, p< 0.001) for HUI3 data;[9] one found the multiplicative gave a 
better fit than the additive method for EQ-5D data;[11] one reported that the minimum 
method outperformed the additive and multiplicative methods for EQ-5D data;[21] one 
reported the ADE outperformed the three traditional nonparametric estimators;[10] and two 
found the combination linear model performed better than the nonparametric estimators, one 
for EQ-5D data,[12] and one for SF-6D data.[13] 
 
 
 
Flanagan tested the multiplicative method on “purified” data by mapping the purified mean 
HSUVs for the single health conditions onto the actual mean HUI3 scores for the CHCs 
(n=278) using OLS regressions.[9] They reported the multiplicative method gave a good fit 
(synergy coefficient (s)=0.99, p<0.001) in CHCs involving two conditions, where a synergy 
coefficient (i.e. the coefficient for the independent variable in a regression model with no 
constant) close to one indicates that the majority of the utility associated with the CHC is 
explained by the product of the HSUVs for the single health conditions. This was supported 
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by testing the multiplicative method in subgroups with three conditions (s = 0.99) from the 
same dataset and in subgroups with either two or three conditions in a second dataset (s= 0.99 
for both).[9]  As reported earlier, while the actual mean HSUVs in Flanagan’s data covered 
the largest range of all the studies, a substantial proportion (184/278) had HUI3 scores above 
0.80. These mean HSUVs are unlikely to be normally distributed suggesting that regressions 
using OLS may not be appropriate.  As the errors in the estimated values were not reported, it 
is not possible to deduce how accurate the multiplicative method was in predicting mean 
HSUVs across the range of the HUI3 index, or to compare these findings with those reported 
in the following studies. 
 
 
 
Both Janssen (CHC: n= 45 and n=166) and Fu (CHC: n=760) compared the additive and 
multiplicative methods using EQ-5D data from the MEPS.[11,21]  Although the studies used 
surveys conducted in different years (Janssen: 2000, 2002; Fu: 2001, 2003) the ranges in 
actual EQ-5D scores for the CHCs were similar (Table 2).  While both studies found the 
multiplicative method outperformed the additive method there were substantial differences in 
their results.  For example Janssen reported MEs of 0.022 and 0.024 for the additive and 
multiplicative methods respectively compared with -0.123 and -0.094 for the additive and 
multiplicative methods when using a baseline of perfect health and -0.054 and -0.043 when 
using purified data in Fu’s study (Table 2). The differences in signs are due to the method 
used to calculate the errors and the difference in magnitude of the errors are possibly due to 
the differences in the baselines used as Janssen used a baseline from individuals without the 
specific health conditions. While Janssen reported the MAEs for both methods were below 
the minimum important difference (MID) for the EQ-5D,[24,26] when plotting the actual and 
estimated mean HSUVs for all CHCs using the data in the article, (Figure 2) it is clear there 
are substantial errors in the individual values estimated by both methods. 
 
 
 
INSERT Figure 2: Actual and estimated HSUVs (using data reported in Janssen’s article) 
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Fu also assessed the minimum method and found this outperformed both the additive and the 
multiplicative methods in terms of MEs, MSEs and paired t-tests obtained from regressing the 
estimated CHC HSUVs onto actual values. Conversely, based on the same statistics, the 
multiplicative method outperformed the minimum method in two other studies that assessed all 
three methods.[12,13] A scatter plot of the actual and estimated HSUVs showed 
heteroskedasticity in the errors in HSUVs estimated using the minimum method with errors 
increasing in magnitude as the actual HSUVs decreased.[12] 
 
 
 
Fu’s article has been superseded by more recent analyses of the data conducted by the same 
group of researchers.[10]  Scatter plots of the estimated and actual HSUVs reported in the 
second article showed approximately 25% of mean HSUVs estimated using the minimum 
method were smaller than the actual mean HSUVs for the CHCs. This is only possible if one 
or more of the mean HSUVs for the single health conditions are smaller than the mean HSUV 
for the corresponding CHC. This is illogical as it implies that a comorbidity will improve 
HRQoL. While one might expect a proportion of irregularities due to random error/noise, 
these anomalies could suggest that the data being combined were not comparable in terms of 
disease severity.  For example a subgroup with the CHC rheumatism and heart disease may 
have a milder form of rheumatism than a subgroup with just rheumatism. 
 
 
 
In addition, the ranges of actual HSUVs estimated differed between the studies which may 
contribute to the difference in the findings.  Fu and Hu estimated HSUVs ranging from 
approximately 0.62 to 0.90 while Ara estimated HSUVs ranging between 0.36 to 0.92 (with 
80% of values smaller than 0.6) for EQ-5D and HSUVs ranging between 0.45 and 0.61 for 
SF-6D.  As mentioned previously, Ara reported errors in the HSUVs estimated using the 
minimum method increased as the actual HSUVs decreased and this was also visible in Hu’s 
smaller range.[10] 
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In addition to estimates obtained using the three traditional methods, Hu predicted HSUVs 
using the linear model obtained by Basu.[14] They compared results with HSUVs estimated 
using a proposed variation of the minimum method which they call the adjusted decrement 
estimator (ADE). They found the ADE method outperformed the others in terms of mean 
errors in estimated HSUVs but the scatter plot of estimated and actual HSUVs showed the 
errors increased substantially as actual HSUVs decreased. Basu’s linear model outperformed 
the three traditional methods in terms of mean errors in predicted HSUVs. Ara used the ADE 
proposed by Hu et al. and found the ME in estimated HSUVs were smaller than those for the 
three traditional methods when using a baseline of perfect health.[12,13]  However, the 
estimated HSUVs were much more accurate for both the multiplicative and the minimum 
methods when using an adjusted baseline and in these analyses the multiplicative method 
performed better than the ADE. 
 
 
 
Overall, Ara found the linear combination model obtained regressing the mean HSUVs for the 
single health conditions onto the corresponding mean HSUV for the CHCs outperformed all 
the nonparametric estimators in both SF-6D and EQ-5D data.[12,13] When examining the 
errors across the range of actual HSUVs they reported that almost all values were under- 
estimated across the full range of values when using the additive method.  For the 
multiplicative method there was a tendency for the errors to decrease for lower HSUVs with 
the largest errors in values above 0.6.  Conversely, for both the minimum and ADE methods 
the errors increased as the actual HSUV decreased.  Although the errors in the HSUVs 
predicted using the OLS models were smaller than those in the other methods, there was a 
tendency to under-predict higher HSUVs and over-predict lower HSUVs. They cautioned 
that while the linear model produced more accurate results than the non parametric 
estimators, none of the coefficients in the model were significant. They recommended that 
their model was validated using external data and suggested an alternative model 
specification may be warranted.  It is worth noting that the mean HSUVs for the actual CHCs 
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were normally distributed in this dataset, whereas HRQoL data, and in particular EQ-5D data 
are typically bimodal with a long negative skew. 
 
 
 
Because of the differences in the five studies such as the methods compared, the preference 
data used, the baseline HSUVs, and the actual range of HSUVs for the CHCs, it is difficult to 
recommend one particular method.  In general, any recommendations by the study authors 
were accompanied by caveats or limitations.  Bias in the estimated values from the additive, 
multiplicative and minimum methods was reported in many of the studies. The statistics 
typically used to assess accuracy of the estimated CHCs, such as mean errors, were not 
particularly informative with regard to systematic errors.  Systematic errors in the estimated 
CHCs were observed in four of the studies and were even visible in the analyses estimating a 
narrow ranges of HSUVs. While MIDs were used as criteria to measure the proportion of 
estimated values within an “acceptable” range in several of the studies, these statistics could be 
perceived as arbitrary as a very small error in a HSUV can make a substantial difference to 
results from decision analytic models where the benefits of treatment are small.  It is clear that 
conclusions drawn can differ when methods are assessed across different ranges of actual 
HSUVs, suggesting the relationship between the HSUVs for the single health conditions and 
the corresponding CHC may not be linear.  In general the analyses using an adjusted baseline 
produced more accurate results.  Overall the parametric approach appears to produce the most 
accurate results and additional research in this area would be beneficial. 
 
 
 
 
 
SUMMARY and SUGGESTIONS FOR FUTURE RESEARCH 
 
This review provides an overview of the current evidence base, describing some of the 
methodological issues when estimating HSUVs for CHCs.  In summary, we found the range 
of actual HSUVs can influence findings; the statistics commonly used to assess the 
performance of the methods were not particularly useful for assessing relevance for 
applications in external data; none of the proposed methods gave consistently accurate results; 
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adjusted baselines increased accuracy.  However, there are caveats associated with this 
conclusion and additional research is required, both of which are discussed below. 
 
 
 
It is clear that the range in actual HSUVs estimated can have a bearing on findings. For 
example, while the minimum method and the ADE performed relatively well in terms of 
mean errors when using a truncated range at the higher end of a utility index,[10,21] these 
methods were less accurate when assessed in subgroups at the lower end of a utility 
index.[12]  While a simple chart showing the actual and estimated HSUVs gives a clear 
picture of systematic bias in estimated values, few of the studies examined systematic bias in 
any detail relying on mean statistics to support their findings. This has implications when 
generalising the results for use in practical applications as decision analytic models frequently 
include health states in the upper and lower quartiles of preference-based utility indices.  For 
example, it is often the case that a lifetime horizon can be appropriate for assessing cost 
effectiveness, where patients are simulated in extreme states of disease severity.  Additional 
research assessing the methods across the full range of the utility indices is required.  There is 
also a need for analysts to be more thorough when assessing performance and reporting 
results. 
 
 
 
The baseline used in the estimating method is important and results from the studies included 
in this review suggest that estimates obtained using an adjusted baseline were more accurate 
in general.  However, acquiring data which is unique to the individual health condition(s) may 
be problematic when the estimation methods are used in future applications where access to 
large datasets are not possible.  Using data (n=1356) collected using the Quality of Well 
Being Index (range 0 to 1) in the Beaver Dam Health Outcomes Study, Fryback et al. proposed 
that analysts conducting cost utility analyses use average age specific HRQoL data from 
population based studies to represent the state of not having a particular condition.[7] This 
may generalise to the area of estimating HSUVs for CHCs and additional research in this area 
would be beneficial. 
24  
 
 
There will inevitably be issues with the definition of the baseline used, including 
inconsistencies in data.  For example, there may be occasions when the mean HSUVs for 
subgroups with a particular health condition are higher than the mean HSUVs for subgroups 
without the health condition,[27] particularly if the data are obtained from different sources. In 
addition, anomalies in data such as the apparent inconsistencies in expected HSUVs for CHCs 
observed in Hu’s dataset require further consideration.[10]  As stated previously, these 
anomalies could suggest that the data being combined are not comparable in terms of disease 
severity.  For example a subgroup who have the CHC rheumatism and heart disease may have 
a milder form of rheumatism than a subgroup who have just rheumatism.  If this is the case, 
then results generated from datasets similar to those used in the studies in this review may not 
be the most appropriate data for testing the methods. Again, research in these areas would be 
informative. 
 
 
 
To our knowledge, no one has assessed the accuracy of the alternative methods in terms of 
estimating HSUVs for subgroups of CHCs classified by type of health condition. It is 
possible that the findings may differ depending on the health dimensions affected by the 
health conditions being combined.  Alternatively, and particularly for prevalent conditions, 
correlations between the HSUVs for particular health conditions could affect the accuracy of 
the methods differently.  Research comparing the accuracy of the methods in subgroups of 
health conditions would add to our understanding.  In addition, no-one has assessed the 
methods using more than one HRQoL instrument within the same dataset. This would be 
informative with regard to generalisability of the results. 
 
 
 
The results from the studies included in this review show that simple linear models tend to 
under-predict higher HSUVs and over-predict lower HSUVs suggesting that an alternative 
model could be warranted. In addition, each preference-based utility index will require a 
25  
different model.  Additional research in this area involving data from a variety of HRQoL 
 
instruments and exploring alternative model forms would be beneficial. 
 
 
 
 
While the use of survey data is attractive due to the relative ease of access and the large 
sample sizes which provide HSUVs for both single and CHCs, there are problems with these 
data. First, the prevalence of health conditions tend to be self-reported and it has been shown 
that the potential for bias is relatively high.  For example 53% of respondents with a 
physician’s diagnosis of diabetes indicated they did not have the condition in a Canadian 
health survey.[8]  Consequently a proportion of respondents identified as not having a 
particular health condition may actually have the health condition which could give 
misleading measurements when analysing data from subgroups of individuals based on self- 
reported health conditions. Second, national surveys tend to recruit randomly from the 
general population living in private households, therefore excluding individuals in residential 
homes and medical establishments.  In general, the latter will have poorer HRQoL than 
individuals in private residents and it is likely that a larger proportion will have CHCs which 
is the data required to evaluate the methods. 
 
 
 
Due to the enormous number of combinations of health conditions it is impractical to obtain 
actual HSUVs for each possible CHC and the volume of resources required is prohibitive.  As 
a consequence, researchers performing cost effectiveness analyses will estimate HSUVs for 
CHCs using data that is readily available such as data from cohorts with the single health 
conditions within the CHC. Although this review has helped to aid understanding of the 
alternative approaches and the potential reasons for differences in reported findings, it is clear 
that additional research is required before a particular method is advocated. 
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Table 1: Summary of studies included in the review 
 
First 
 
Author 
Utility 
 
measure 
Data source 
 
[study year(s)] 
Single Health Conditions Comorbid Health 
 
Conditions (n=number of 
Methods compared Authors conclusions/ 
 
favoured method 
 
(Year) 
 
 
(n=number of cases 
 
 
actual CHC HSUVs 
  
  
 
in dataset) 
 
 
estimated) 
  
Studies using utilities elicited directly from patients 
Esnaola Standard Patients with cancer, pain, Two CHCs (n=3) Additive Multiplicative predict 
 
(2001) 
 
gamble 
 
recurrent rectal 
 
complications, 
 
cancer and pain, cancer and 
 
Multiplicative 
 
better than additive and 
 
[19] 
 
 
cancer 
 
residual cancer after 
 
complications, and residual 
 
 
additive may under- 
  
 
(n=50) 
 
surgery 
 
cancer after surgery 
 
 
estimate utilities for 
 
CHCs. 
 
Dale 
 
TTO 
 
Patients attending 
 
impotence, incontinence, 
 
Two CHCs (n=3) 
 
Additive 
 
All 3 models are 
 
(2008) 
 
 
prostate biopsy 
 
watchful waiting, post- 
 
impotence plus either 
 
Multiplicative 
 
biased. 
 
[18] 
 
 
clinics 
 
prostatectomy 
 
incontinence, watchful 
 
Minimum 
 
Minimum model 
  
 
(n=147) 
 
 
waiting or post- 
 
prostatectomy 
 
 
recommended if cannot 
 
elicit CHC HSUVs 
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directly. 
 
Basu 
(2009) 
[14] 
TTO Patients attending 
prostate biopsy 
clinics 
(n=207) 
 
75% model 
formation, 25% 
model validation 
impotence, incontinence, 
watchful waiting, post- 
prostatectomy 
Two CHCs (n=3) 
impotence plus either 
incontinence, watchful 
waiting or post- 
prostatectomy 
Additive 
Multiplicative 
Minimum 
linear model 
Regression 
combination model is 
the best approach. 
 
Preference-based data (individual patient level HSUVs) 
 
Wee SF-6D Sample of ethnic, Diabetes, hypertension, Two CHCs (n=3) Additive In favour of additive 
 
(2005)  
 
Chinese, Malays 
 
heart disease, 
 
diabetes plus one of: 
 
Synergistic 
 
method 
 
[22] 
 
 
and Indians in 
 
musculoskeletal illnesses 
 
hypertension 
 
Subtractive 
 
  
 
Singapore 
 
 
heart disease [ 
  
  
 
(n=5,224) 
 
 
musculoskeletal illnesses 
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Hanmer 
 
(2009) 
SF-6D Medicare Health 
 
Outcomes Survey 
15 self-reported health 
 
conditions 
65 years and over: 
 
(n=58) for two CHCs, 
Additive 
 
Minimum 
Multiplicative was the 
 
best 
 
[20] 
 
 
[1998-2004] 
 
 
(n=35) for three CHCs, 
 
Multiplicative 
 
  
 
Split into ≥65 or 
 
 
(n=26) for four CHCs 
  
  
 
<65 years 
 
 
(n=8) for five CHCs 
  
  
 
(n=95,195) model 
 
 
(n=NR) for > 6 CHCs 
  
  
 
formation; 
 
(n= 94,794)  model 
 
 
Under 65 years: n=NR 
  
 
validation 
 
Preference-based data (mean HSUVs) 
 
Flanaga 
 
HUI3 
 
Canadian 
 
26 self-reported chronic 
 
Cycle 1.1 (formulation): 
 
Multiplicative 
 
In favour of 
 
n 
 
 
Community Health 
 
conditions 
 
(n=278) for two CHCs 
 
 
multiplicative method 
 
(2005) 
 
[9] 
 
 
Survey (CCHS) 
 
Cycle 1.1 [2000- 
 
 
(n=924) for three CHCs 
 
Cycle 2.1 (validation): 
  
  
 
2001] (n=131,535) 
 
 
(n=299) for two CHCs 
  
  
 
model formation; 
 
 
(n=734) for three CHCs 
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Cycle 2.1 [2003- 
 
2004] (n=45,101) 
 
model validation 
 
 
Janssen 
(2008) 
[11] 
EQ-5D MEPS Medical 
Expenditure Panel 
Survey [2000, 
2002] 
(n=38,678) 
Conditions defined by 
ICD-9 codes and 
subgrouped into: 
a) Quality Priority 
 
Conditions (QPC) giving 
 
10 chronic conditions 
present any time in the 
past (except joint pain) 
b) Clinical Classification 
 
Categories (CCC) giving 
 
259 conditions 
QPC: two CHCs (n=45) 
CCC: two CHCs (n=166) 
Additive 
 
Multiplicative 
Multiplicative method 
shows a better fit 
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Fu 
 
(2008) 
EQ-5D Medical 
 
Expenditure Panel 
Clinical classification 
 
Categories system (CCC), 
Two CHCs (n=760) Additive 
 
Multiplicative 
None of the methods 
 
provide an unbiased 
 
[21] 
 
 
Survey 
 
defined by ICD-9 codes 
 
 
Minimum 
 
estimate but the 
  
 
[2001, 2003] 
  
 
Maximum 
 
minimum outperformed 
  
 
(n=40,846) 
  
 
Average 
 
the others 
 
Mean of condition 
 
with smaller 
 
sample 
 
Hu 
 
EQ-5D 
 
Medical 
 
Clinical classification 
 
Two CHCs (n=760) 
 
Additive 
 
The ADE generated 
 
(2010) 
 
 
Expenditure Panel 
 
Categories system (CCC), 
 
 
Multiplicative 
 
unbiased estimates for 
 
[10] 
 
 
Survey 
 
using combinations of 
 
 
Minimum 
 
joint health states 
  
 
[2001, 2003] 
 
ICD-9 codes 
 
 
ADE 
 
  
 
(n=40,846) 
  
 
Linear 
 
model[Basu] 
 
 
Ara 
 
EQ-5D 
 
Health Survey for 
 
Self-reported chronic 
 
Two CHCs (n=91) 
 
Additive 
 
The linear model gave 
 
(2010) 
 
 
England 
 
health conditions, 39 
 
 
Multiplicative 
 
the most accurate 
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[12]  [2003, 2004, 2005, 
 
2006] 
individually categorised 
 
and 15 grouped 
 Minimum 
 
ADE 
results but there were 
 
some substantial 
  
 
(n=41,174) 
 
conditions 
 
 
OLS combination 
 
individual errors 
 
Ara 
 
SF-6D 
 
Welsh Health 
 
Self-reported limiting 
 
Two CHCs (n=32) 
 
Additive 
 
The linear model gave 
 
(2010) 
 
 
Survey 
 
long-standing health 
 
 
Multiplicative 
 
most accurate results 
 
[13] 
 
 
[2003, 2004, 2005, 
 
conditions, 39 
 
 
Minimum 
 
but there were some 
  
 
2007, 2008] 
 
(n=64,437) 
 
individually categorised 
 
and 14 grouped health 
 
 
ADE 
 
OLS combination 
 
substantial individual 
 
errors 
 
conditions 
 
ICD = International Classification of Diseases, Ninth Revision, Clinical Modification 
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Table 2: Reported results and supporting statistics 
 
Statistics used to compare the methods used to estimate HSUVs 
 
Methods used ME 
 
(95% CI) 
MSE 
 
(95% CI) MAE 
Ccc 
 
(95% CI) s t-test 
 
Studies using utilities elicited directly from patients 
 
Esnaola[19] (SG) range in CHC median HSUVs: all 0.50 
 
Additive Median absolute error: range 0.300 to 0.350 
 
Multiplicative Median absolute error: range 0.100 to 0.188 
 
Dale [18] (TTO) range in CHC mean HSUVs: 0.66 to 0.72 
 
Additive 0.127 0.256* 0.282 -0.533 NR NR 
Multiplicative 0.091 0.218* 0.276 -0.406 NR NR 
Minimum 0.038 0.194* 0.260 -0.305 NR NR 
Basu [14] (TTO) range in CHC mean HSUVs: 0.63 to 0.70 
Additive 0.0855 to 0.1152 0.0627 to 0.0711 NR -0.5361to -0.4707 NR NR 
Multiplicative 0.0497 to 0.0838 0.0475 to 0.0502 NR -0.3404 to -0.4280 NR NR 
Minimum 0.0008 to 0.0356 0.0400 to 0.0510 NR -0.2459 to -0.3407 NR NR 
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Linear model -0.005 to 0.0228 0.0329 to 0.0463 NR 0.0006 to 0.0682 NR NR 
 
Studies predicting HSUVs using individual patient level data from generic HRQoL questionnaires 
 
Wee [22] (SF-6D) range in CHC HSUVs: not reported 
 
Additive None of statistics reported: effect of 2
nd 
chronic medical condition was generally additive rather than synergistic or subtractive 
 
Hanmer [20] (SF-6D) under 65 years [over 65 years] range in CHC HSUVs: NR 
 
Additive NR 0.0088 [0.0104] NR NR NR NR 
Multiplicative NR 0.0087 [0.0103] NR NR NR NR 
Minimum NR 0.0092 [0.0113] NR NR NR NR 
Studies estimating mean HSUVs using subgroups with single health conditions and data from generic HRQoL questionnaires 
 
Flanagan [9] (HUI3) all HSUVs “purified” by dividing data by mean HSUV from full dataset, range in mean CHC HSUVs: -0.01 to 1.00 
 
Multiplicative NR NR NR NR 0.99
~
, p<0.001 NR 
Janssen [11] (EQ-5D) adjusted baseline using mean HSUV from respondents without the specific health condition, 
Health conditions identified by QPC, range in mean CHC HSUVs: 0.594 – 0.798 
 
Additive 0.027† 0.003† 0.040 NR NR p<0.001 
 
Multiplicative 0.010† 0.002† 0.032 NR NR p=0.082 
 
Janssen (EQ-5D) adjusted baseline using mean HSUV from respondents without the specific health condition, 
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Health conditions identified by CCC, range in mean CHC HSUVs: 0.611 – 0.742 
 
Additive 0.022† 0.001† 0.022 NR NR p<0.001 
 
Multiplicative 0.024† 0.001† 0.022 NR NR p=0.289 
 
Fu [21] (EQ-5D), baseline of perfect health, range in mean CHC HSUVs: 0.611 – 0.742 
 
Additive                      -0.123                      0.0156                         NR                          0.2184                     NR (s<0.970)                                  NR 
Multiplicative              -0.094                      0.0095                         NR                          0.2752                     NR (s<0.970)                                  NR 
Minimum                    0.025                      0.0021                         NR                          0.5578                   0.970, p<0.0001                                NR 
Fu [21] (EQ-5D), all HSUVs “purified” by dividing data by mean HSUV from full dataset, range in mean CHC HSUVs: 0.62 to 0.90 
Additive -0.054  0.0035  NR  NR  0.842[23]  NR 
Multiplicative -0.043 0.0025  NR  NR  0.878[23]  NR 
Minimum  0.027 0.0024 NR NR 1.029[23] NR 
Hu [10] (EQ-5D), baseline of perfect health, range in mean CHC HSUVs: 0.62 to 0.90 
0.023 0.045* 0.56 
 
Minimum (0.021, 0.026) (-0.024, 0.023) NR (0.52, 0.59) NR NR 
 
-0.096 0.100* 0.28 
 
Multiplicative ( -0.098, -0.094) ( -0.114, -0.079) NR (0.25, 0.30) NR NR 
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 -0.125 0.127*  0.22 NR NR 
 
Additive 
 
(–0.127, -0.124) 
 
(-0.141,-0.111) 
 
NR 
 
(0.20, 0.23) 
  
 
 
0.0001 
 
0.034* 
 
 
0.72 
 
NR 
 
NR 
 
ADE 
 
(-0.002,0.002) 
 
(-0.024, 0.023) 
 
NR 
 
( 0.70, 0.75) 
  
 
 
-0.016 
 
0.040* 
 
 
0.60 
 
NR 
 
NR 
 
Linear index 
 
(–0.018, -0.013) 
 
(-0.043, 0.010) 
 
NR 
 
(0.58, 0.62) 
  
Ara [12] (EQ-5D), baseline of perfect health, range in mean CHC HSUVs: 0.36 to 0.92 
 
Additive 
 
0.1384 
 
0.0234 
 
0.1411 
 
NR 
 
NR 
 
NR 
 
Multiplicative 
 
0.0580 
 
0.0070 
 
0.0707 
 
NR 
 
NR 
 
NR 
 
Minimum 
 
-0.0995 
 
0.0147 
 
0.1037 
 
NR 
 
NR 
 
NR 
 
ADE 
 
-0.0470 
 
0.0064 
 
0.0620 
 
NR 
 
NR 
 
NR 
 
OLS model 
 
0.0003 
 
0.0036 
 
0.0471 
 
NR 
 
NR 
 
NR 
Ara [12] (EQ-5D), age-adjusted baseline from individuals with none of health conditions, range in mean CHC HSUVs: 0.36 to 0.92 
 
Additive 
 
0.0781 
 
0.0102 
 
0.0872 
 
NR 
 
NR 
 
NR 
 
Multiplicative 
 
0.0254 
 
0.0042 
 
0.0516 
 
NR 
 
NR 
 
NR 
 
Minimum 
 
-0.0995 
 
0.0147 
 
0.1037 
 
NR 
 
NR 
 
NR 
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ADE -0.0695 0.0090 0.0781 NR NR NR 
 
OLS model 
 
0.0001 
 
0.0036 
 
0.0466 
 
NR 
 
NR 
 
NR 
Ara [13] (SF-6D), age-adjusted baseline from individuals with none of health conditions, range in mean CHC HSUVs: 0.465 to 0.607 
 
Additive 
 
0.1209 
 
0.0157 
 
0.1209 
 
NR 
 
NR 
 
NR 
 
Multiplicative 
 
0.0745 
 
0.0064 
 
0.0745 
 
NR 
 
NR 
 
NR 
 
Minimum 
 
-0.0546 
 
0.0038 
 
0.0546 
 
NR 
 
NR 
 
NR 
 
ADE 
 
0.0383 
 
0.0022 
 
0.0006 
 
NR 
 
NR 
 
NR 
 
OLS model 
 
0.0000 
 
0.0006 
 
0.0191 
 
NR 
 
NR 
 
NR 
 
Bold text = model favoured in study conclusions, ME = mean error, MAE = mean absolute error, MSE = mean squared error, ccc=concordance correlation 
coefficient, s=synergist coefficient in OLS (mapping estimated onto actual HSUVs with no constant), t-test for estimated and actual CHC HSUVs, NR = Not 
reported 
* root mean squared error reported not MSE, † estimated from actual HSUVs and estimated HSUVs reported in article 
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Figure 1: Impact on HRQoL attributable to health condition(s) 
 
 
Impact on HRQoL 
attributable to history 
of heart attack/angina 
 
 
1 = Perfect health 
Impact on HRQoL 
attributable to 
arthritis/rheumatism 
 
 
Average HSUV for individuals (n=558) with 
no history of heart attack/angina  (aged 70) 0.813 
 
0.869 
Average HSUV for individuals (n=460) with 
no history arthritis/rheumatism (aged 65) 
 
 
 
0.181 0.368 
Average HSUV for individuals (n=1,759) with 
a history of heart attack/angina  (average age 
= 70) 
 
0.632 
 
 
0.597 
 
Average HSUV for individuals (n=1,648) with 
a history of arthritis/rheumatism (average age 
= 65) 0.272 0.403 
 
 
 
 
 
 
 
0 = Dead 
40  
E
st
im
at
e
d
 E
Q
-5
D
 s
co
re
s 
Figure 2: Actual and estimated HSUVs (using data reported in Janssen’s article) 
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